ClearAlpha Technologies LP Cuts Position in DaVita Inc. (NYSE:DVA)

ClearAlpha Technologies LP trimmed its holdings in shares of DaVita Inc. (NYSE:DVA) by 39.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 1,879 shares of the company’s stock after selling 1,217 shares during the period. ClearAlpha Technologies LP’s holdings in DaVita were worth $308,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Transcendent Capital Group LLC purchased a new position in DaVita during the third quarter valued at $25,000. Blue Trust Inc. raised its position in shares of DaVita by 58.6% in the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after purchasing an additional 78 shares during the last quarter. Family Firm Inc. bought a new position in DaVita in the 2nd quarter worth about $43,000. Friedenthal Financial purchased a new stake in DaVita during the 2nd quarter valued at about $48,000. Finally, Point72 Hong Kong Ltd purchased a new position in DaVita in the second quarter worth about $68,000. 90.12% of the stock is owned by institutional investors.

DaVita Stock Performance

DVA stock opened at $163.74 on Tuesday. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. DaVita Inc. has a 1 year low of $103.40 and a 1 year high of $169.51. The company has a market cap of $13.43 billion, a P/E ratio of 17.66, a price-to-earnings-growth ratio of 0.94 and a beta of 0.90. The stock’s fifty day moving average price is $158.57 and its 200-day moving average price is $149.48.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The firm had revenue of $3.26 billion during the quarter, compared to analysts’ expectations of $3.25 billion. During the same period in the previous year, the business posted $2.85 earnings per share. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. On average, equities analysts forecast that DaVita Inc. will post 9.71 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on DVA. Truist Financial increased their price target on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a report on Monday, October 7th. Bank of America lifted their target price on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a report on Wednesday, August 7th. Barclays upped their price target on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Finally, UBS Group lifted their price objective on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $161.80.

Insider Buying and Selling

In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the transaction, the chief executive officer now directly owns 837,835 shares in the company, valued at approximately $138,284,666.75. This trade represents a 5.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.00% of the stock is currently owned by insiders.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.